The Western blot remains widely used, despite facing many challenges—such as poor quantitation, high variability, and large time, sample consumption, and labor requirements.
Simple Western™ platforms, developed by ProteinSimple, a Bio-Techne brand, employ capillary electrophoresis to automate protein separation and immunodetection in conventional Western blotting. This process eliminates many tedious and error-prone steps, delivering quantitative results in as little as 3 hours.
The transfer of Western blot assays to Simple Western is uncomplicated, and often the same antibodies can be utilized. More than 3000 antibodies from various vendors have been validated for Simple Western.
Cell Signaling Technology® (CST) offers high-quality research-use antibodies, implementing stringent validation procedures to ensure the specificity, sensitivity, and reproducibility of the antibodies. CST is the largest third-party supplier of antibodies validated for Simple Western, contributing to nearly 25 % of all antibodies validated so far.
In this webinar, Dr. Chris LaBreck will present a customer’s viewpoint regarding the simplicity of transferring conventional western blotting assays, which use high-quality antibodies from CST, onto the Jess instrument of Simple Western, demonstrating the high-performance of CST antibodies on Simple Western.
With the automation and efficiency offered by the Jess system, a pilot study successfully screened over 100 CST antibodies within two months, with an 83 % pass rate.
CST and Bio-Techne have an ongoing, long-term partnership to continue validating antibodies on the Jess platform. The webinar will also offer an overview of Simple Western technology and its crucial benefits.
About the speaker
